Skip to Content

Wilate FDA Approval History

FDA Approved: Yes (First approved December 4, 2009)
Brand name: Wilate
Generic name: von Willebrand Factor/Coagulation Factor VIII Complex (Human)
Dosage form: Injection
Company: Octapharma USA
Treatment for: von Willebrand Disease

Wilate is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD).

Development Timeline for Wilate

DateArticle
Dec  8, 2009Approval Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.